UPDATE July 25, 2016: Active Ownership Capital today announced that it has submitted a supplementary motion as well as counter motions for the agenda of the Annual General Meeting of STADA Arzneimittel AG (ISIN DE0007251803) on August 26, 2016. The objective is to enable a comprehensive restart of the company‘s corporate governance by completely replacing the shareholder representatives in the Supervisory Board. The four new candidates have been chosen by a renowned executive search consultancy firm in a professional process with participation of those major shareholders that followed AOC’s call for shareholder participation in the Aktionärsforum in the German Bundesanzeiger and got in contact with the executive search consultancy firm. A corresponding press release and the CVs of the proposed candidates can be found linked below.

On this website, Active Ownership Capital is making available information to the shareholders of STADA Arzneimittel AG. Currently, more than 5% of the shares in STADA are attributed to Active Ownership Capital.

Active Ownership Capital is an independent, partner-managed investment company, which pursues a constructive and long-term investment approach, investing in undervalued publicly listed companies. Active Ownership Capital follows an active ownership approach and fosters value creation through operational, strategic and structural improvements. We firmly believe that a strengthened Supervisory Board is a major step to developing STADA further together with the management and realize its high value creation potential.

Shareholders of STADA Arzneimittel AG who wish to support the proposals of Active Ownership Capital, can either vote correspondingly at the Annual General Meeting on August 26, 2016 or grant voting proxy rights at no charge. A corresponding form is anticipated to be available as of August 2, 2016 on this website.

Press contact:
Phone: +49 69 794 090 80